Emerging infections: surveillance, epidemiology and pathogenesis

新发感染：监测、流行病学和发病机制

基本信息

批准号：
10626403
负责人：
DAVID WANG
金额：
$ 24.71万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-11 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10626403
关键词：
2019-nCoV Address Animal Model Antibodies Antibody Response Antigens Antiviral Therapy Arthropod Vectors Attenuated Biological Assay Borrelia burgdorferi Bourbon virus CD8-Positive T-Lymphocytes COVID-19 pandemic Cellular Assay Centers for Disease Control and Prevention (U.S.)Cost of Illness Data Disease Disease model Enzyme-Linked Immunosorbent Assay Epidemiology Future Glycoproteins Goals Health Heartland virus Human Immune Immune Sera Immune response Immunity Immunize Incidence Infection Knowledge Life Lyme Disease Meningitis Messenger RNA Modeling Mus Neisseria Pathogenesis Population Powassan virus Process Proteins RNA Viruses RNA vaccine Rodent Model SARS-CoV-2 infection Salivary Proteins Scientist Streptococcus pneumoniae T cell response T-Lymphocyte Technology Testing Tick-Borne Diseases Tick-Borne Encephalitis Virus Ticks United States Vaccine Antigen Vaccine Design Vaccines Viral Viral Antigens Viral Envelope Proteins Virus Virus-like particle adaptive immunity climate change combat demographics design economic cost enzyme linked immunospot assay immunogenic immunogenicity improved in vivo influenzavirus lipid nanoparticle mouse model neutralizing antibody novel virus pathogen pathogenic virus prevent societal costs tick bite tick transmission tick-borne tick-borne pathogen tick-borne virus transmission process universal vaccine vaccine access vaccine development vaccine evaluation vector vector control virology

项目摘要

PROJECT SUMMARY The incidence of tick-borne diseases has increased significantly over the past 25 years due to climate change, shifting population demographics of both humans and ticks, and inadequate vector control. Including economic and societal costs, it is estimated that tick-borne diseases costs between 50 and 100 billion dollars each year. The Center for Disease Control and Prevention currently recognizes 18 different tick-transmitted pathogens in the United States. This number is likely to rise as novel viruses and pathogens are being discovered each year. One of these pathogens is Bourbon virus (BRBV), an emerging tick-borne RNA virus that can infect and cause disease in humans. No antiviral therapies or vaccines are available, highlighting the need to develop countermeasures against these life-threatening diseases. The primary objective of this application is to develop an mRNA vaccine against BRBV, evaluate its efficacy in vivo in a mouse model of BRBV and determine the mechanism of action. A secondary goal is to test different viral antigens and mRNA vaccine designs to improve multivalent mRNA vaccines. Successful completion of the proposed studies will provide the preliminary data for a R01 application aimed at developing a universal vaccine that confers protection against tick and tick-borne pathogens in the United States.

项目概要由于气候变化，过去 25 年来蜱传疾病的发病率显着增加，人类和蜱虫种群数量的变化以及病媒控制不足。包括经济和社会成本，据估计，蜱传疾病每年造成 50 至 1000 亿美元的损失。疾病控制与预防中心目前已识别出 18 种不同的蜱传播病原体美国。随着每年新病毒和病原体的发现，这个数字可能还会上升。其中一种病原体是波旁病毒 (BRBV)，这是一种新兴的蜱传 RNA 病毒，可以感染并导致人类疾病。目前还没有可用的抗病毒疗法或疫苗，这凸显了开发抗病毒疗法或疫苗的必要性针对这些危及生命的疾病的对策。该应用程序的主要目标是开发针对 BRBV 的 mRNA 疫苗，在 BRBV 小鼠模型中评估其体内功效并确定作用机制。第二个目标是测试不同的病毒抗原和 mRNA 疫苗设计，以改善多价 mRNA 疫苗。拟议研究的成功完成将为以下方面提供初步数据 R01 申请旨在开发一种通用疫苗，提供针对蜱虫和蜱传病毒的保护美国的病原体。